PMID- 12022908
OWN - NLM
STAT- MEDLINE
DCOM- 20030211
LR  - 20170214
IS  - 1060-0280 (Print)
IS  - 1060-0280 (Linking)
VI  - 36
IP  - 6
DP  - 2002 Jun
TI  - Therapeutic equivalency of low-molecular-weight heparins.
PG  - 1042-57
AB  - OBJECTIVE: To review the recent literature on the approved uses of enoxaparin, 
      dalteparin, ardeparin, and tinzaparin and the evidence for therapeutic 
      equivalence. DATA SOURCES: A MEDLINE search (1993-January 2001) was conducted to 
      identify English-language literature available on enoxaparin, dalteparin, 
      ardeparin, and tinzaparin. STUDY SELECTION: All controlled trials evaluating 
      low-molecular-weight heparins (LMWHs) versus standard therapy powered to detect a 
      significant difference were reviewed. DATA EXTRACTION: Agents were reviewed with 
      regard to safety and efficacy. DATA SYNTHESIS: As a class, LMWHs have chemical, 
      physical, and clinical similarities. LMWHs have greater bioavailability, longer 
      half-lives, a more predictable pharmacologic response, possible improved safety, 
      and similar or greater efficacy compared with unfractionated heparin (UFH). 
      Because of this, enoxaparin, dalteparin, ardeparin, and tinzaparin are being 
      considered as alternatives to UFH or warfarin, and there is potential for 
      therapeutic interchange. Evaluation of clinical trials is limited because of 
      differing diagnostic methods, drug administration times, dose equivalencies, and 
      outcome measurements. CONCLUSIONS: Only 1 trial has evaluated 2 LMWHs in a direct 
      comparison in the same study. There is insufficient evidence for determining the 
      therapeutic equivalence of LMWHs.
FAU - McCart, Gary M
AU  - McCart GM
AD  - Department of Clinical Pharmacy, School of Pharmacy, University of California, 
      San Francisco 94143-0622, USA. gmccart@itsa.ucsf.edu
FAU - Kayser, Steven R
AU  - Kayser SR
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
SB  - IM
MH  - Angina, Unstable/drug therapy
MH  - Animals
MH  - Anticoagulants/administration & dosage/adverse 
      effects/*pharmacokinetics/*therapeutic use
MH  - Arthroplasty, Replacement, Hip
MH  - Arthroplasty, Replacement, Knee
MH  - Controlled Clinical Trials as Topic
MH  - Heparin, Low-Molecular-Weight/administration & dosage/adverse 
      effects/*pharmacokinetics/*therapeutic use
MH  - Humans
MH  - Myocardial Infarction/drug therapy
MH  - Therapeutic Equivalency
MH  - Venous Thrombosis/drug therapy/prevention & control
RF  - 66
EDAT- 2002/05/23 10:00
MHDA- 2003/02/13 04:00
CRDT- 2002/05/23 10:00
PHST- 2002/05/23 10:00 [pubmed]
PHST- 2003/02/13 04:00 [medline]
PHST- 2002/05/23 10:00 [entrez]
AID - 10.1345/aph.10264 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2002 Jun;36(6):1042-57. doi: 10.1345/aph.10264.